BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 24, 2010
 |  BC Week In Review  |  Company News  |  Deals

AlphaRx, Cypress Bioscience deal

Cypress informed partner AlphaRx that it discontinued funding for development of Indaflex, a topical cream formulation of indomethacin. In 2007, Indaflex missed the primary endpoints in a Phase II trial to treat osteoarthritis (OA)....

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >